Diana J Schreier1, Kianoush B Kashani2,3, Ankit Sakhuja3, Kristin C Mara4, Mohammad S Tootooni5, Heather A Personett1, Sarah Nelson1, Andrew D Rule2, James M Steckelberg6, Aaron J Tande6, Erin F Barreto1,7. 1. Department of Pharmacy, Mayo Clinic, Rochester, Minnesota. 2. Division of Nephrology and Hypertension, Mayo Clinic, Rochester, Minnesota. 3. Division of Pulmonary and Critical Care Medicine, Mayo Clinic, Rochester, Minnesota. 4. Division of Biomedical Statistics and Informatics, Mayo Clinic, Rochester, Minnesota. 5. Department of Health Sciences Research, Mayo Clinic, Rochester, Minnesota. 6. Division of Infectious Diseases, Mayo Clinic, Rochester, Minnesota. 7. Robert D. and Patricia E. Kern Center for the Science of Health Care Delivery, Mayo Clinic, Rochester, Minnesota.
Abstract
BACKGROUND: Nephrotoxins contribute to 20%-40% of acute kidney injury (AKI) cases in the intensive care unit (ICU). The combination of piperacillin-tazobactam (PTZ) and vancomycin (VAN) has been identified as nephrotoxic, but existing studies focus on extended durations of therapy rather than the brief empiric courses often used in the ICU. The current study was performed to compare the risk of AKI with a short course of PTZ/VAN to with the risk associated with other antipseudomonal β-lactam/VAN combinations. METHODS: The study included a retrospective cohort of 3299 ICU patients who received ≥24 but ≤72 hours of an antipseudomonal β-lactam/VAN combination: PTZ/VAN, cefepime (CEF)/VAN, or meropenem (MER)/VAN. The risk of developing stage 2 or 3 AKI was compared between antibiotic groups with multivariable logistic regression adjusted for relevant confounders. We also compared the risk of persistent kidney dysfunction, dialysis dependence, or death at 60 days between groups. RESULTS: The overall incidence of stage 2 or 3 AKI was 9%. Brief exposure to PTZ/VAN did not confer a greater risk of stage 2 or 3 AKI after adjustment for relevant confounders (adjusted odds ratio [95% confidence interval] for PTZ/VAN vs CEF/VAN, 1.11 [.85-1.45]; PTZ/VAN vs MER/VAN, 1.04 [.71-1.42]). No significant differences were noted between groups at 60-day follow-up in the outcomes of persistent kidney dysfunction (P = .08), new dialysis dependence (P = .15), or death (P = .09). CONCLUSION: Short courses of PTZ/VAN were not associated with a greater risk of short- or 60-day adverse renal outcomes than other empiric broad-spectrum combinations.
BACKGROUND: Nephrotoxins contribute to 20%-40% of acute kidney injury (AKI) cases in the intensive care unit (ICU). The combination of piperacillin-tazobactam (PTZ) and vancomycin (VAN) has been identified as nephrotoxic, but existing studies focus on extended durations of therapy rather than the brief empiric courses often used in the ICU. The current study was performed to compare the risk of AKI with a short course of PTZ/VAN to with the risk associated with other antipseudomonal β-lactam/VAN combinations. METHODS: The study included a retrospective cohort of 3299 ICU patients who received ≥24 but ≤72 hours of an antipseudomonal β-lactam/VAN combination: PTZ/VAN, cefepime (CEF)/VAN, or meropenem (MER)/VAN. The risk of developing stage 2 or 3 AKI was compared between antibiotic groups with multivariable logistic regression adjusted for relevant confounders. We also compared the risk of persistent kidney dysfunction, dialysis dependence, or death at 60 days between groups. RESULTS: The overall incidence of stage 2 or 3 AKI was 9%. Brief exposure to PTZ/VAN did not confer a greater risk of stage 2 or 3 AKI after adjustment for relevant confounders (adjusted odds ratio [95% confidence interval] for PTZ/VAN vs CEF/VAN, 1.11 [.85-1.45]; PTZ/VAN vs MER/VAN, 1.04 [.71-1.42]). No significant differences were noted between groups at 60-day follow-up in the outcomes of persistent kidney dysfunction (P = .08), new dialysis dependence (P = .15), or death (P = .09). CONCLUSION: Short courses of PTZ/VAN were not associated with a greater risk of short- or 60-day adverse renal outcomes than other empiric broad-spectrum combinations.
Authors: Megan K Luther; Tristan T Timbrook; Aisling R Caffrey; David Dosa; Thomas P Lodise; Kerry L LaPlante Journal: Crit Care Med Date: 2018-01 Impact factor: 7.598
Authors: Tamar F Barlam; Sara E Cosgrove; Lilian M Abbo; Conan MacDougall; Audrey N Schuetz; Edward J Septimus; Arjun Srinivasan; Timothy H Dellit; Yngve T Falck-Ytter; Neil O Fishman; Cindy W Hamilton; Timothy C Jenkins; Pamela A Lipsett; Preeti N Malani; Larissa S May; Gregory J Moran; Melinda M Neuhauser; Jason G Newland; Christopher A Ohl; Matthew H Samore; Susan K Seo; Kavita K Trivedi Journal: Clin Infect Dis Date: 2016-05-15 Impact factor: 9.079
Authors: Drayton A Hammond; Melanie N Smith; Jacob T Painter; Nikhil K Meena; Katherine Lusardi Journal: Pharmacotherapy Date: 2016-04-01 Impact factor: 4.705
Authors: Ravindra L Mehta; Maria T Pascual; Sharon Soroko; Brandon R Savage; Jonathan Himmelfarb; T Alp Ikizler; Emil P Paganini; Glenn M Chertow Journal: Kidney Int Date: 2004-10 Impact factor: 10.612
Authors: Lior Fuchs; Joon Lee; Victor Novack; Yael Baumfeld; Daniel Scott; Leo Celi; Tal Mandelbaum; Michael Howell; Daniel Talmor Journal: Chest Date: 2013-09 Impact factor: 9.410
Authors: Ravindra L Mehta; John A Kellum; Sudhir V Shah; Bruce A Molitoris; Claudio Ronco; David G Warnock; Adeera Levin Journal: Crit Care Date: 2007 Impact factor: 9.097
Authors: Claire Rimes-Stigare; Paolo Frumento; Matteo Bottai; Johan Mårtensson; Claes-Roland Martling; Max Bell Journal: Crit Care Date: 2015-11-03 Impact factor: 9.097
Authors: Adam M Blevins; Jennifer N Lashinsky; Craig McCammon; Marin Kollef; Scott Micek; Paul Juang Journal: Antimicrob Agents Chemother Date: 2019-04-25 Impact factor: 5.191
Authors: Emily L Joyce; Sandra L Kane-Gill; Priyanka Priyanka; Dana Y Fuhrman; John A Kellum Journal: J Am Soc Nephrol Date: 2019-09-09 Impact factor: 10.121
Authors: Brian Pacca Elliott; Michael M Tang; Joshua Alexander Madden; Ronald James Markert; Steven Dale Burdette; Craig Matthew Pleiman; Emily Claire Speelmon Journal: Intern Emerg Med Date: 2021-06-05 Impact factor: 5.472
Authors: Joseph M Yabes; Laveta Stewart; Faraz Shaikh; Paul M Robben; Joseph L Petfield; Anuradha Ganesan; Wesley R Campbell; David R Tribble; Dana M Blyth Journal: J Intensive Care Med Date: 2020-06-08 Impact factor: 2.889
Authors: Richard G Wunderink; Arjun Srinivasan; Philip S Barie; Jean Chastre; Charles S Dela Cruz; Ivor S Douglas; Margaret Ecklund; Scott E Evans; Scott R Evans; Anthony T Gerlach; Lauri A Hicks; Michael Howell; Melissa L Hutchinson; Robert C Hyzy; Sandra L Kane-Gill; Erika D Lease; Mark L Metersky; Nancy Munro; Michael S Niederman; Marcos I Restrepo; Curtis N Sessler; Steven Q Simpson; Sandra M Swoboda; Christina Vazquez Guillamet; Grant W Waterer; Curtis H Weiss Journal: Ann Am Thorac Soc Date: 2020-05
Authors: Kate S Grattan; Mohamed Mohamed Ali; Seyed M Hosseini-Moghaddam; Hayley J I Gilmour; Gregory P Crunican; Erica Hua; Kelly A Muhsin; Rochelle Johnstone; Lise C Bondy; Megan K Devlin; Sarah Shalhoub; Sameer Elsayed; Michael S Silverman Journal: JAC Antimicrob Resist Date: 2021-01-18